Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.56 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.43 |
| ▸ | PRKACA | P17612 | 2/20 | 0.43 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.43 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | NMT2 | O60551 | 2/20 | 0.43 |
| ▸ | NMT1 | P30419 | 2/20 | 0.43 |
| ▸ | CCKAR | P32238 | 1/20 | 0.40 |
| ▸ | CCKBR | P32239 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14500432 | 1.00 | GLP1R (0.56) | GLP1RTLR2ROCK2PRKACAAKT3 | |
| SCHEMBL14500437 | 0.92 | GLP1R (0.48) | GLP1RTLR2ROCK2PRKACAAKT3 | |
| SCHEMBL14500471 | 0.90 | GLP1R (0.54) | GLP1RTLR2ROCK2PRKACAAKT3 | |
| SCHEMBL8116615 | 0.90 | GLP1R (0.58) | GLP1RTLR2ROCK2PRKACAAKT3 | |
| SCHEMBL14500465 | 0.90 | GLP1R (0.55) | GLP1RTLR2CCKARCCKBR | |
| SCHEMBL17369669 | 0.90 | GLP1R (0.55) | GLP1RTLR2CCKARCCKBR | |
| SCHEMBL8107176 | 0.89 | GLP1R (0.48) | GLP1RCCKARCCKBR | |
| SCHEMBL13474957 | 0.88 | GLP1R (0.55) | GLP1RTLR2ROCK2PRKACAAKT3 | |
| SCHEMBL12972429 | 0.88 | GLP1R (0.61) | GLP1RTLR2ROCK2PRKACAAKT3 | |
| SCHEMBL12147595 | 0.88 | GLP1R (0.58) | GLP1RTLR2ROCK2PRKACAAKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040210041-A1 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | ARBOGAST CHRISTOPHE (FR) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040210041-A1 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | MKI67, TP53, VHL | GLP1R 4619/4885TLR2 4510/4885ROCK2 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.